2. Search Result
Search Result
Results for "

Compound+52

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15154
    NG 52
    10+ Cited Publications

    Compound 52

    		 CDK Cancer
    NG 52 is a potent, cell-permeable, selective, ATP-compatible and orally active Cdc28p and Pho85p kinase inhibitor with IC50s of 7 μM and 2 μM, respectively. NG 52 also inhibits the activity of phosphoglycerate kinase 1 (PGK1) with an IC50 of 2.5 μM. NG 52 is inactive against yeast kinases Kin28p, Srb10, and Cak1p .
    NG 52
  • HY-139092
    IL-4-inhibitor-1
    3 Publications Verification

    		 Interleukin Related Infection Cancer
    IL-4-inhibitor-1 (compound 52) is an IL-4 inhibitor, with an EC50 of 1.81 µM .
    IL-4-inhibitor-1
  • HY-150029
    CB1/2 agonist 3

    		Cannabinoid Receptor Neurological Disease
    CB1/2 agonist 3 (compound 52), a potent non-selective cannabinoid ligand, is a CB1/CB2 (cannabinoid receptor) competitive agonist. CB1/2 agonist 3 acts on hCB1 and hCB2 with Ki values of 5.9 nM and 3.5 nM, respectively .
    CB1/2 agonist 3
  • HY-151243
    NCATS-SM1441

    		Lactate Dehydrogenase Cancer
    NCATS-SM1441 (compound 52) is a lactate dehydrogenase (LDH) inhibitor (IC50=40 nM). By inhibiting the activity of LDH, NCATS-SM1441 is able to reduce the production of lactic acid in cancer cells, helping to slow or stop the proliferation of cancer cells. NCATS-SM1441 can be used to study cancer metabolism .
    NCATS-SM1441
  • HY-143604
    KRAS G12D inhibitor 11

    		Ras Cancer
    KRAS G12D inhibitor 11 is a potent inhibitor of KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D inhibitor 11 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021108683A1, compound 52) .
    KRAS G12D inhibitor 11
  • HY-15154R
    NG 52 (Standard)

    Compound 52 (Standard)

    		 CDK Reference Standards Cancer
    NG 52 (Standard) is the analytical standard of NG 52. This product is intended for research and analytical applications. NG 52 is a potent, cell-permeable, selective, ATP-compatible and orally active Cdc28p and Pho85p kinase inhibitor with IC50s of 7 μM and 2 μM, respectively. NG 52 also inhibits the activity of phosphoglycerate kinase 1 (PGK1) with an IC50 of 2.5 μM. NG 52 is inactive against yeast kinases Kin28p, Srb10, and Cak1p .
    NG 52 (Standard)
  • HY-151514
    Antituberculosis agent-5

    		Bacterial Infection
    Antituberculosis agent-5 (compound 52) is a nitrofuranylamide derivative, inhibits M. tuberculosis UDP-Gal mutase. Antituberculosis agent-5 inhibits Glf activity with an IC50 value of 99 μM/mL and resists tuberculosis (TB) with a MIC value of 1.6 μg/mL .
    Antituberculosis agent-5
  • HY-175507
    TRPMPZQ-IN-1

    		Parasite TRP Channel Infection
    TRPMPZQ-IN-1 (Compound 52) is a TRPMPZQ inhibitor, with an EC50 of 0.38 μM against TRPMPZQ from Spirometra erinaceieuropaei. TRPMPZQ-IN-1 exhibits antiparasitic activity, showing an EC50 of 4.3 μM against Echinococcus multilocularis. TRPMPZQ-IN-1 can be used in antiparasitic research .
    TRPMPZQ-IN-1
  • HY-175867
    PROTAC SMARCA2 degrader-34

    		PROTACs Epigenetic Reader Domain Cancer
    PROTAC SMARCA2 degrader-34 (compound 52) is a selective SMARCA2 PROTAC degrader (DC50 in HeLa cell: < 0.1 μM for SMARCA2, > 1 μM for SMARCA4). PROTAC SMARCA2 degrader-34 can be used for study of cancer. (Pink: SMARCA2 ligand (HY-178414) ; Blue: E3 ligand (HY-168055) ; Black: linker) .
    PROTAC SMARCA2 degrader-34
  • HY-155425
    ICMT-IN-17

    		ICMT Cancer
    ICMT-IN-17 (compound 52) is an inhibitor of ICMT (IC50=0.38 μM) .
    ICMT-IN-17
  • HY-157578
    COX-2-IN-38

    		COX Inflammation/Immunology
    COX-2-IN-38 (compound 52*) is a potent inhibitor of COX-2, with the IC50 value of 79.4 nM .
    COX-2-IN-38
  • HY-162560
    Antitumor agent-162

    		LXR Cancer
    Antitumor agent-162 (compound 52a) is a potent and orally active antitumor agent. Antitumor agent-162 shows cytotoxicity .
    Antitumor agent-162
  • HY-161625
    Kv7.2 modulator 2

    		Potassium Channel Neurological Disease
    Kv7.2 modulator 2 (compound 52) is a Kv7.2 channel modulator and can be used for study of epilepsy .
    Kv7.2 modulator 2
  • HY-161417
    LIMK-IN-2

    		LIM Kinase (LIMK) Cancer
    LIMK-IN-2 (Compound 52) is an LIMK inhibitor. LIMK-IN-2 can suppress the cell migration of osteosarcoma and cervical cancer cells, demonstrating potential anti-angiogenic activity .
    LIMK-IN-2
  • HY-169303
    Gpr35 modulator 2

    		GPR35 Inflammation/Immunology
    Gpr35 modulator 2 (compound 52) is a GPR35 modulator. Gpr35 modulator 2 can be used for the study of a various GPR35-related disorders .
    Gpr35 modulator 2
  • HY-162442
    pan-KRAS-IN-9

    		Ras Cancer
    pan-KRAS-IN-9 (Compound 52) is an inhibitor for in human tumor mutated genes KRAS, which inhibits proliferation of KRAS mutated cells AsPC-1 (G12D mutant) and SW480 (G12V mutant) with IC50 of 0.24 and 0.30 nM, respectively .
    pan-KRAS-IN-9
  • HY-119724
    ABCG2-IN-3

    		BCRP Cancer
    ABCG2-IN-3 (Compound 52) is a selective inhibitor for breast cancer resistance protein (ABCG2), with an IC50 of 0.238 µM. ABCG2-IN-3 reverses the ABCG2-mediated resistance toward SN-38 and inhibit the ATPase activity .
    ABCG2-IN-3
  • HY-148449
    eIF4A3-IN-15

    		Eukaryotic Initiation Factor (eIF) Cancer
    eIF4A3-IN-15 (compound 52) is a Silvestrol (HY-13251) analogue. eIF4A3-IN-15 interferes the assembling of eIF4F translation complex with EC50s of 11, 700 and 120 nM for myc-LUC, tub-LUC and the growth inhibition for MBA-MB-231 cells. eIF4A3-IN-15 can be used for the research of human cancer pathogenesis .
    eIF4A3-IN-15
  • HY-112880
    c-(2'FdAMP-2'FdIMP)

    		Drug Derivative STING NF-κB IFNAR Interleukin Related Infection Cancer
    c-(2'FdAMP-2'FdIMP) (Compound 52),a derivative of cAIMP (HY-134375), is a cyclic dinucleotide (CDN). c-(2'FdAMP-2'FdIMP) is a STING activator and significantly induce STING-dependent IRF and NF-κB pathway signaling. c-(2'FdAMP-2'FdIMP) can be used for STING-based immunotherapy, such as cancers and infectious diseases research .
    c-(2'FdAMP-2'FdIMP)
  • HY-176996
    Ape1/Ref-1 redox-IN-1

    		DNA/RNA Synthesis Cancer
    Ape1/Ref-1 redox-IN-1 (Compound 52) is an Ape1/Ref-1 redox inhibitor. Ape1/Ref-1 redox-IN-1 can be used in the research of cancer .
    Ape1/Ref-1 redox-IN-1
  • HY-181300
    PROTAC EZH2 Degrader-17

    		PROTACs Histone Methyltransferase Cancer
    PROTAC EZH2 Degrader-17 (compound 52) is a PROTAC protein degrader targeting EZH2 with an antiproliferative IC50 of 18.32 μM in lymphoma cells. PROTAC EZH2 Degrader-17 exhibits antiproliferative activity against lymphoma cells. PROTAC EZH2 Degrader-17 can be used for the research of lymphoma .
    PROTAC EZH2 Degrader-17
  • HY-181790
    DOT1L ligand-2

    		Ligands for Target Protein for PROTAC Histone Methyltransferase Cancer
    DOT1L ligand-2 (Compound 52) is a DOT1L ligand. DOT1L ligand-2 acts as a Ligand for Target Protein for PROTAC, which is used to develop and design degraders of PROTAC DOT1L, such as DOT1L808 (HY-181789). DOT1L ligand-2 is applicable to research related to MLL-rearranged leukemia .
    DOT1L ligand-2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: